uploads///Chart  Vac

Quarterly Performance of GlaxoSmithKline’s Vaccines Segment

By

Oct. 5 2017, Updated 7:39 a.m. ET

Vaccines segment

GlaxoSmithKline’s (GSK) Vaccines segment includes various forms of vaccines classified by the use of vaccines such as meningitis vaccines, influenza vaccines, and established vaccines. GlaxoSmithKline acquired the meningitis vaccines and other vaccines business from Novartis (NVS).

The above chart shows revenues for the Vaccines segment over the last few quarters. Each of the franchises in the segment reported revenue growth in 2Q17.

Article continues below advertisement

2Q17 performances

The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, including a 5.0% rise at constant exchange rates and an 11.0% positive impact of foreign exchange.

Revenues for overall vaccines have risen due to the inclusion of the acquired meningitis vaccine Bexsero, which had strong sales in the US, European, and international markets. Revenues also rose due to strong sales for Menveo in the European and international markets.

Geographical performance

In 2Q17, GlaxoSmithKline’s US markets reported a 22.0% rise in revenues to 316.0 million pounds compared to 2Q16. That included a 12.0% rise in revenues at constant exchange rates and a positive impact of foreign exchange. The US markets reported a rise in sales of Bexsero and Menveo from the meningitis portfolio as well as a rise in sales for Infanrix and Pediarix from the established vaccines portfolio, partially offset by lower sales of Rotarix.

Article continues below advertisement

The European markets reported a 21.0% rise in revenues to 394.0 million pounds in 2Q17 compared to 2Q16, including a 10.0% rise in revenues at constant exchange rates and a positive impact of foreign exchange. The European markets reported increased sales for Bexsero and Menveo from the meningitis portfolio, Pediarix and Rotarix from the established vaccines portfolio, and Fluarix and FluLaval from the influenza vaccines portfolio.

International markets, excluding the US and European markets, reported a 6.0% rise in revenues to 401.0 million pounds in 2Q17 compared to 2Q16. That included a 5.0% fall in revenues at constant exchange rates, which was more than offset by an 11.0% positive impact of foreign exchange. The fall in revenues was due to lower sales of all vaccines except Bexsero, Boostrix, and Cervarix.

The First Trust Value Line Dividend ETF (FVD) has 0.50% of its total assets in GlaxoSmithKline (GSK). FVD also has 0.50% in Merck & Co. (MRK), 0.50% in Eli Lilly (LLY), and 0.50% in Abbott Laboratories. (ABT).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.